Acetaminophen-induced proliferation of breast cancer cells involves estrogen receptors

Toxicology and Applied Pharmacology

Volumn 155, Issue 3, 1999, Pages 273-279

  Harnagea Theophilus, Eugenia ^a   Gadd, Samantha L ^a   Knight Trent, April H ^a   DeGeorge, George L ^b   Miller, Michael R ^a,b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b M B Research Laboratories   (United States)

Author keywords

Acetaminophen; Antiestrogens; Breast cancer cells; Proliferation

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; HYDROXYTAMOXIFEN; PARACETAMOL;

ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE S PHASE; CELL ISOLATION; CELL PROLIFERATION; DNA SYNTHESIS INHIBITION; ENZYME ACTIVITY; GRANULOSA CELL; HUMAN; HUMAN CELL; RECEPTOR BINDING; TARGET CELL;

EID: 0033560022     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1006/taap.1998.8619     Document Type: Article

References (42)

1. Ameer, B., and Greenblatt, D. (1977). Acetaminophen. Ann. Int. Med. 87, 202-209.
2. Anstead, G. M., Carlson, K. E., and Katzenellenbogen, J. A. (1997). The estradiol pharmacophore: Ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids 62, 268-303.
3. Atkinson, A., and Roy, D. (1995). In vivo genotoxicity of bisphenol A. Environ. Mutagen. 26, 60-67.
4. Berkenstam, A., Glaumann, H., Martin, M., Gustafsson, J. A., and Norstedt, G. (1989). Hormonal regulation of estrogen receptor messenger ribonucleic acid in T47Dco and MCF-7 breast cancer cells. Mol. Endocrinol. 3, 22-28.
5. Bond, G. P., McGinnin, P. M., Cheever, K. L., Harris, S. J., Plotnik, H. B., and Nemeier, R. W. (1980). Reproductive effects of bisphenol A. Proc. Soc. Taxicol. 19, A23.
6. Boyd, E. M. (1970). Testicular atrophy from analgesic drugs. J. Clin. Pharmacol. 10, 222-227.
7. Branham, W. S., Fishman, R., Streck, R. D., Medlock, K. L., DeGeorge, J. J., and Sheehan, D. M. (1996). ICI 182,780 inhibits endogenous estrogen-dependent rat uterine growth and tamoxifen-induced developmental toxicity. Biol Reprod. 54, 160-167.
8. Castles, C. G., Klotz, D. M., Fuqua, S. A., and Hill, S. M. (1995). Coexpression of wildtype and variant oestrogen receptor mRNAs in a panel of human breast cancer cell lines. Br. J. Cancer 71, 974-980.
9. Cramer, D. W., Harlow, B. L., Titus-Ernstoff, L., Bohlke, K., Welch, W. R., and Greenberg, E. R. (1998a). Over-the-counter analgesics and risk of ovarian cancer. Lancet 351, 104-107.
10. Cramer, D. W., Liberman, R. F., Hornstain, M. D., McShane, P., Powers, D., Li, E. Y., and Barbieri, R. (1998b). Basal hormone levels in women who use acetaminophen for menstrual pain. Fertil. Steril. 70, 371-373.
11. Cunningham, A. R., Klopman, G., Rosenkranz, H. S. (1997). A dichotomy in the lipophilicity of natural estrogens, xenoestrogens, and phytoestrogens. Environ. Health Perspect. 105, 665-668.
12. Dabre, P., Yates, J., and Curtis, S. (1983). Effect of estradiol on human breast cancer cells in culture. Cancer Res. 43, 349-353.
13. De Cupris, A., and Favoni, R. E. (1997). Oestrogen/growth factor cross-talk in breast carcinoma: A specific target for novel antiestrogens. Trends Pharmacol. Sci. 18, 245-251.
14. Dewhurst, L. O., Gee, J. W., Rennie, I. G., and MacNeil, S. (1997). Tamoxifen, 17beta-oestradiol and the calmodulin antagonist J8 inhibit human melanoma cell invasion through fibronectin. Br. J. Cancer 75, 860-868.
15. Forrest, J. A. H., Clements, J. A., and Prescott, L. F. (1982). Clinical pharmacokinetics of paracetamol. Clin. Pharmacokinet. 7, 93-107.
16. Gould, J. C., Leonard, L. S., Maness, S. C., Wagner, B. L., Conner, K., Zacharewski, T., Safe, S., McDonell, D. P., Gaido, K. W. (1998). Bisphenol A interacts with the estrogen receptor α in a distinct manner from estradiol. Mol. Cell. Endocrinol. 142, 203-214.
17. Graham, M. L., II, Dalquist, K. E., and Horwitz, K. B. (1989). Simultaneous measurement of progesterone receptors and DNA indices by flow cytometry: Analysis of breast cancer cell mixtures and genetic instability if the T47D line. Cancer Res. 49, 3943-3949.
18. Graham, M. L., II, Krett, N. L., Miller, L. A., Leslie, K. K., Gordon, D. F., Wood, W. M., Wei, L. L., and Horwitz, K. B. (1990). T47Dco cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance. Cancer Res. 50, 6208-6217.
19. Haney, A. F., Hughes, S. F., and Hughes, C. L., Jr. (1987). Effects of acetaminophen and nonsteroidal antiinflamatory drugs on progesterone production by porcine granulosa cells in vitro. Reprod. Toxicol. 1, 285-291.
20. Harnagea-Theophilus, E., and Miller, M. R. (1999). Acetaminophen alters estrogenic responses in vitro: Stimulation of DNA synthesis in estrogen-responsive human breast cancer cells Toxicol. Sci. (in press).
21. Harnagea-Theophilus, E., Miller, M. R., and Rao, N. (1999). Positional isomers of acetaminophen differentially induce proliferation of cultured breast cancer cells. Toxicol. Lett. (in press).
22. Horwitz, K. B., and Freidenberg, G. R. (1985). Growth inhibition and increase of insulin receptors in antiestrogen-resistant T47Dco human breast cancer cells by progestins: Implications for endocrine therapies. Cancer Res. 45, 167-173.
23. Horwitz, K. B., Wei, L. L., and Francis, M. D. (1986). Structural analyses of progesterone receptors. J. Steroid. Biochem. 24, 109-117.
24. International Agency for Research on Cancer (IARC) (1979). Sex hormones. IARC Monogr. Eval. Carcinog. Risk Chem. Hum. 21, 173-221.
25. Isenhower, W. D., Newbold, R. R., Cefalo, R. C., Korach, K. S., and McLachlan, J. A. (1986). Absence of estrogenic activity in some drugs commonly used during pregnancy. Biol. Res. Pregnancy Perinatol. 7, 6-10.
26. Jaiyesimi, I. A., Buzdar, A. U., and Decker, D. A. (1995). Use of tamoxifen for breast cancer: Twenty years later. J. Clin. Oncol. 13, 513-529.
27. Jensen, K. J., Poulsen, H. E., Doemer, J., and Loft, S. (1996). Paracetamol-induced spindle disturbances in V79 cells with and without expression of CYP1A2. Pharmacol. Toxicol. 78, 224-228.
28. Kastrup, E. K., Ed. (1981). Antipyretic analgesics. In Facts and Comparisons, pp. 774-777. Facts and Comparisons, St. Louis.
29. Kasid, A., Bronzert, D., and Lippman, M. (1985). Estradiol responsive human breast cancer cells in culture. In Sex Steroid Receptors, Field Educational Italia ACTA MEDICA, 238-254.
30. Leslie, K. K., Tasset, D. M., and Horwitz, K. B. (1992). Functional analysis of mutant estrogen receptor isolated from T47Dco breast cancer cells. Am. J. Obstet. Gynecol. 166, 1053-1061.
31. Miller, M. R., Wentz, E., and Ong, S. (1999). Acetaminophen alters estrogenic responses in vitro: Inhibition of estrogen-dependent vitellogenin production in trout liver cells. Toxicol. Sci. (in press).
32. Nagel, S. C., vom Saal, F. S., and Welson, W. V. (1998). The effective free fraction of estradiol and xenoestrogens in human serum measured by whole cell uptake assays: Physiology of delivery modifies estrogenic activity. Proc. Soc. Exp. Biol. Med. 217, 300-309.
33. Noyes, W. R., Mulcahy, R. T., Craig, B. A., and Kinsella, T. J. (1996). Effect of a pure anti-estrogen, ICI 182,780, on the in vitro radiosensitivity of MCF-7 breast carcinoma cells. Radiat. Oncol. Invest. 3, 232-237.
34. Osborne, C. K., Coronado-Heinsohn, E. B., Hilsenbeck, S. G., McCue, B. L., Wakeling, A. E., McClelland, R. A., Manning, D. L., and Nicholson, R. I. (1995). Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J. Natl. Cancer Inst. 87, 746-750.
35. Prescott, L. F. (1996). Paracetamol (Acetaminophen). A Critical Bibliographic Review. Taylor & Francis, Bristol, PA.
36. Reel, J. R., Davis, L. A., and Lamb, J. C., IV. (1992). Reproductive toxicity evaluation of acetaminophen in Swiss CD-1 mice using a continuous breeding protocol. Fundam. Appl. Toxicol. 18, 233-239.
37. Roy, D., Palangat, M., Chen, C. W., Thomas, R. D., Colerangle, J., Atkinson, A., and Yan, Z. J. (1997). Biochemical and molecular changes at the cellular level in response to exposure to environmental estrogen-like chemicals. J. Toxicol. Environ. Health 50, 1-29.
38. Santti, A. R. (1996). Wood-derived estrogens: Studies in vitro with breast cancer cells lines and in vivo with trout. Toxicol. Appl. Pharmacol. 136, 381-388.
39. Soto, A. M., Justicia, H., Wray, J. W., and Sonnenschein, C. (1991). P-nonylphenol: An estrogenic xenobiotic released from "modified" polystyrene. Environ. Health Perspect. 92, 167-173.
40. Soto, A., Sonnenschein, C., Chung, K. L., Fernandez, M. F., Olea, N., and Serrano, F. O. (1995). The E-screen assay as a tool to identify estrogen: An update on estrogenic environmental pollutants. Environ. Health Perspect. 103, 113-122.
41. Strobl, S. J., Kasid, A., Huff, K. K., and Lippman, M. E. (1984). Kinetic alterations in estrogen receptors associated with estrogen receptor processing in human breast cancer cells. Endocrinology 115, 1116-1124.
42. Teicher, B. A., Holden, S. A., Ara, G., Liu, J-T. C., Robinson, M. F., Flodgren, P., Dupuis, N., and Northey, D. (1993). Cyclooxygenase inhibitors: In vitro and in vivo effects on antitumor alkylating agents in the EMT-6 murine mammary carcinoma. Int. J. Oncol. 2, 145-153.